Background and Objectives: Brolucizumab is a novel anti-vascular endothelial growth factor (VEGF). whose efficacy has been shown in the Hawk and Harrier phase 3 clinical studies. The goal of the present case series is to report initial results of brolucizumab intravitreal injections (IVI) on type 3 neovascularization in neovascular age-related macular degeneration (nAMD). evaluated by... https://halohealthcarers.shop/product-category/socks/